This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

November 12, 2026

Company name: Modalis Therapeutics Corporation
Stock exchange listing: Tokyo Stock Exchange
Code number: 4883
URL: https://www.modalistx.com/en/
Representative: Haruhiko Morita

Notice Regarding the Recording of Non-Operating Income (Foreign Exchange Income)

Modalis Therapeutics Corporation (hereafter, "the Company") hereby announces the recording of non-operating income for the nine months ended September 30, 2026 (January 1 – September 30, 2026).

1. Details of non-operating income

For the nine months ended September 30, 2026, the Company recorded foreign exchange gains of 5 million yen as non-operating income due to fluctuations in foreign exchange rates. These gains arose mainly from foreign currency-denominated assets and liabilities held by the Group. This amount is subject to change depending on future movements in foreign exchange rates.

2. Impact on earnings

The above non-operating income is reflected in the "Consolidated Financial Results for the Nine Months Ended September 30, 2026 (Japanese GAAP)" disclosed on November 12, 2026.